CA3188951A1 - Polysaccharide derivative, polysaccharide derivative-drug conjugate, and method for producing same - Google Patents

Polysaccharide derivative, polysaccharide derivative-drug conjugate, and method for producing same

Info

Publication number
CA3188951A1
CA3188951A1 CA3188951A CA3188951A CA3188951A1 CA 3188951 A1 CA3188951 A1 CA 3188951A1 CA 3188951 A CA3188951 A CA 3188951A CA 3188951 A CA3188951 A CA 3188951A CA 3188951 A1 CA3188951 A1 CA 3188951A1
Authority
CA
Canada
Prior art keywords
polysaccharide
aba
group
polysaccharide derivative
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3188951A
Other languages
English (en)
French (fr)
Inventor
Taichi Ito
Seiichi Ohta
Pan QI
Arvind Kumar Singh CHANDEL
Mitsuko Isaji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mochida Pharmaceutical Co Ltd
University of Tokyo NUC
Original Assignee
Mochida Pharmaceutical Co Ltd
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharmaceutical Co Ltd, University of Tokyo NUC filed Critical Mochida Pharmaceutical Co Ltd
Publication of CA3188951A1 publication Critical patent/CA3188951A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B11/00—Preparation of cellulose ethers
    • C08B11/02—Alkyl or cycloalkyl ethers
    • C08B11/04—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals
    • C08B11/14—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals with nitrogen-containing groups
    • C08B11/15—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals with nitrogen-containing groups with carbamoyl groups, i.e. -CO-NH2
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3188951A 2020-08-14 2021-08-10 Polysaccharide derivative, polysaccharide derivative-drug conjugate, and method for producing same Pending CA3188951A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-137010 2020-08-14
JP2020137010 2020-08-14
PCT/JP2021/029573 WO2022034889A1 (ja) 2020-08-14 2021-08-10 多糖誘導体、多糖誘導体－薬物コンジュゲート、その製造方法

Publications (1)

Publication Number Publication Date
CA3188951A1 true CA3188951A1 (en) 2022-02-17

Family

ID=80247958

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3188951A Pending CA3188951A1 (en) 2020-08-14 2021-08-10 Polysaccharide derivative, polysaccharide derivative-drug conjugate, and method for producing same

Country Status (8)

Country Link
US (1) US20230285577A1 (https=)
EP (1) EP4198060A4 (https=)
JP (2) JP7721539B2 (https=)
KR (1) KR20230061346A (https=)
CN (2) CN116322642B (https=)
AU (1) AU2021324708A1 (https=)
CA (1) CA3188951A1 (https=)
WO (1) WO2022034889A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023157150A1 (ja) * 2022-02-16 2023-08-24 持田製薬株式会社 多糖誘導体の用途
CN115991883B (zh) * 2022-12-26 2024-07-16 四川大学华西医院 一种用于消化道esd的水凝胶及其制备方法和用途
CN120267903B (zh) * 2025-06-06 2025-08-08 吉林大学 一种免疫调控水凝胶及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2855307B2 (ja) * 1992-02-05 1999-02-10 生化学工業株式会社 光反応性グリコサミノグリカン、架橋グリコサミノグリカン及びそれらの製造方法
JP4565691B2 (ja) 2000-02-28 2010-10-20 株式会社Phg ヘパリン結合性成長因子用徐放基材、およびヘパリン結合性成長因子徐放剤
RU2283848C1 (ru) * 2005-06-16 2006-09-20 Институт нефтехимии и катализа РАН Республика Башкортостан Способ получения конъюгатов альгиновой кислоты
ITMI20061726A1 (it) * 2006-09-11 2008-03-12 Fidia Farmaceutici Derivati crosslinkati a base di acido ialuronico reticolato via click chemistry
JPWO2008096547A1 (ja) * 2007-02-07 2010-05-20 焼津水産化学工業株式会社 組織滞留性キトサンゲルを含有する抗腫瘍剤組成物
IT1399351B1 (it) * 2009-06-16 2013-04-16 Fidia Farmaceutici Procedimento per la sintesi di coniugati di glicosamminoglicani (gag) con molecole biologicamente attive, coniugati polimerici e usi relativi
WO2014038641A1 (ja) * 2012-09-05 2014-03-13 中外製薬株式会社 アミノ酸およびステリル基が導入されたヒアルロン酸誘導体
EP3778653B1 (en) 2018-03-28 2025-07-09 Mochida Pharmaceutical Co., Ltd. Novel reactive alginic acid derivatives
JP7088075B2 (ja) 2019-02-22 2022-06-21 株式会社デンソー 電子制御装置

Also Published As

Publication number Publication date
CN116322642B (zh) 2024-08-23
EP4198060A4 (en) 2024-09-04
EP4198060A1 (en) 2023-06-21
JP7721539B2 (ja) 2025-08-12
US20230285577A1 (en) 2023-09-14
JPWO2022034889A1 (https=) 2022-02-17
AU2021324708A1 (en) 2023-03-09
JP2025156408A (ja) 2025-10-14
KR20230061346A (ko) 2023-05-08
WO2022034889A1 (ja) 2022-02-17
CN118955760A (zh) 2024-11-15
CN116322642A (zh) 2023-06-23

Similar Documents

Publication Publication Date Title
EP4480507A1 (en) Use of polysaccharide derivative
Tan et al. Controlled gelation and degradation rates of injectable hyaluronic acid‐based hydrogels through a double crosslinking strategy
Rinaudo Main properties and current applications of some polysaccharides as biomaterials
US9044529B2 (en) Hydrogel tissue adhesive formed from aminated polysaccharide and aldehyde-functionalized multi-arm polyether
KR101966555B1 (ko) 생체친화형 하이드로젤 및 제조방법
JP2025156408A (ja) 多糖誘導体、多糖誘導体－薬物コンジュゲート、その製造方法
WO2008067655A1 (en) Biocompatible hydrogel-based scaffolds
CN103897206B (zh) N,o-羧甲基化壳聚糖-多醛基透明质酸凝胶及其用途
WO2009006780A1 (en) A method for the formation of a rapid-gelling biocompatible hydrogel and the preparation of a spraying agent
CN102585303A (zh) 一种壳聚糖/聚赖氨酸原位凝胶及其制备方法
Tsai et al. Injectable, shear-thinning, self-healing, and self-cross-linkable benzaldehyde-conjugated chitosan hydrogels as a tissue adhesive
Ito et al. Chitosan gel sheet containing drug carriers with controllable drug-release properties
US20120053331A1 (en) Glycol chitosan derivative, preparation method thereof and drug delivery system comprising the same
Ye et al. In situ formation of adhesive hydrogels based on PL with laterally grafted catechol groups and their bonding efficacy to wet organic substrates
US7879818B2 (en) Hyaluronic acid-based cross-linked nanoparticles
JP2023081477A (ja) 多糖誘導体、多糖誘導体を含む架橋構造体、架橋構造体の製造方法
Mahmoud Nasef et al. Preparation and properties of non‐crosslinked and ionically crosslinked chitosan/agar blended hydrogel films
AU2012313983B2 (en) Multilayer implants for delivery of therapeutic agents
CN117815431A (zh) 生物粘合剂及其制备、使用方法
JP2025532434A (ja) ベンゼンジオール官能基およびその酸化形で疎水性修飾されたバイオポリマー
US9795717B2 (en) Enzymatically degradable compositions
WO2019172261A1 (ja) 食道狭窄防止材料
송원문 Development and Biomedical Applications of Anti-inflammatory Hydrogels Based on Functionalized Polysaccharides
CN118662428A (zh) 一种基于立体复合作用的凝胶及其制备方法和应用
Dai et al. Injectable Shear‐Thinning Polyampholyte Hydrogel Derived From Functionalized Hyaluronan for pH‐Responsive Prevention of Postoperative Peritoneal Adhesions

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240724

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250709

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250709

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250716

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250716

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250716

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250717

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250924

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250924

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250924

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250924

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250924